However, as a single agent, apatinib provided remarkable survival benefits in the third-line treatment of gastric cancer versus placebo (14).The exact reason is unclear, but in terms of the mechanism, bevacizumab is a monoclonal antibody directed against VEGFA that acts by binding and neutralizing all VEGFA isoforms (6). The gene discussed is VEGFA; the disease is gastric cancer.